Man Group plc Takes $1.09 Million Position in Disc Medicine, Inc. $IRON

Key Points

• Man Group plc acquired a new $1.09 million stake in Disc Medicine during the second quarter, purchasing 14,925 shares and owning approximately 0.39% of the company. Institutional investors collectively hold 83.7% of IRON’s outstanding shares.
• Disc Medicine reported quarterly EPS of -$1.54, beating analysts’ consensus estimate of -$1.71. The stock opened at $80.05, with a 12-month range of $40.00 to $99.50.
• Analyst sentiment remains broadly positive, with ten Buy ratings, one Hold and one Sell; the average price target is $107.70. However, company insiders sold approximately $11.4 million in shares over the past 90 days.

Man Group plc bought a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 14,925 shares of the company's stock, valued at approximately $1,092,000. Man Group plc owned 0.39% of Disc Medicine as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NEXTBio Capital Management LP acquired a new position in Disc Medicine during the fourth quarter valued at approximately $3,397,000. DNB Asset Management AS increased its position in shares of Disc Medicine by 1,425.8% in the fourth quarter. DNB Asset Management AS now owns 84,255 shares of the company's stock worth $6,691,000 after acquiring an additional 78,733 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Disc Medicine in the fourth quarter worth $2,152,000. Vanguard Group Inc. raised its stake in shares of Disc Medicine by 22.1% in the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock valued at $140,371,000 after acquiring an additional 319,621 shares during the period. Finally, BlackRock Inc. purchased a new position in shares of Disc Medicine in the 2nd quarter valued at $180,502,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Insider Buying and Selling

In related news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company's stock, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 34,000 shares of Disc Medicine stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total value of $2,387,140.00. Following the sale, the chief executive officer owned 226,064 shares in the company, valued at $15,871,953.44. This represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 153,612 shares of company stock worth $11,431,811. 3.76% of the stock is currently owned by corporate insiders.

Disc Medicine Price Performance

Shares of IRON stock opened at $80.05 on Thursday. The company has a market capitalization of $3.07 billion, a PE ratio of -12.17 and a beta of 0.98. The firm has a fifty day simple moving average of $77.49 and a 200-day simple moving average of $70.15. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. Equities research analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wedbush upped their price target on shares of Disc Medicine from $88.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday. Wall Street Zen lowered Disc Medicine from a "hold" rating to a "sell" rating in a research report on Saturday, August 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a research note on Friday, July 17th. Morgan Stanley reaffirmed an "overweight" rating and issued a $90.00 target price on shares of Disc Medicine in a research report on Monday, August 17th. Finally, HC Wainwright increased their target price on Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $107.70.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source